FISIOLOGÍA Y FARMACOLOGÍA
Departamento
Universitat de Barcelona
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Universitat de Barcelona (27)
2024
-
Sensitization of cholangiocarcinoma cells to chemotherapy through BCRP inhibition with β-caryophyllene oxide
Biomedicine and Pharmacotherapy, Vol. 170
2023
-
Cohort Profile: PISCIS, a population-based cohort of people living with HIV in Catalonia and Balearic Islands
International Journal of Epidemiology, Vol. 52, Núm. 4, pp. E241-E252
-
Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance
Nature Reviews Gastroenterology and Hepatology, Vol. 20, Núm. 7, pp. 462-480
-
Identification and experimental validation of druggable epigenetic targets in hepatoblastoma
Journal of Hepatology, Vol. 79, Núm. 4, pp. 989-1005
-
The outcome of boosting mitochondrial activity in alcohol-associated liver disease is organ-dependent
Hepatology (Baltimore, Md.), Vol. 78, Núm. 3, pp. 878-895
2022
-
Beneficial effect of ursodeoxycholic acid in patients with acyl-CoA oxidase 2 (ACOX2) deficiency–associated hypertransaminasemia
Hepatology, Vol. 76, Núm. 5, pp. 1259-1274
-
Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry
Journal of Hepatology, Vol. 76, Núm. 5, pp. 1109-1121
-
Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions
Gut, Vol. 71, Núm. 8, pp. 1669-1683
2021
-
Anti-miR-518d-5p overcomes liver tumor cell death resistance through mitochondrial activity
Cell Death and Disease, Vol. 12, Núm. 6
-
NADPH oxidase 4 (Nox4) deletion accelerates liver regeneration in mice
Redox Biology, Vol. 40
-
STARD1 promotes NASH-driven HCC by sustaining the generation of bile acids through the alternative mitochondrial pathway
Journal of Hepatology, Vol. 74, Núm. 6, pp. 1429-1441
-
Synthetic Conjugates of Ursodeoxycholic Acid Inhibit Cystogenesis in Experimental Models of Polycystic Liver Disease
Hepatology, Vol. 73, Núm. 1, pp. 186-203
-
The tgf-β pathway: A pharmacological target in hepatocellular carcinoma?
Cancers, Vol. 13, Núm. 13
2020
-
4-Aryl-1-oxa-4,9-diazaspiro[5.5]undecane Derivatives as Dual μ-Opioid Receptor Agonists and σ1 Receptor Antagonists for the Treatment of Pain
Journal of Medicinal Chemistry, Vol. 63, Núm. 5, pp. 2434-2454
-
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
Nature Reviews Gastroenterology and Hepatology, Vol. 17, Núm. 9, pp. 557-588
-
Discovery of EST73502, a Dual μ-Opioid Receptor Agonist and σ1Receptor Antagonist Clinical Candidate for the Treatment of Pain
Journal of Medicinal Chemistry, Vol. 63, Núm. 24, pp. 15508-15526
2016
-
Pharmacogenomic analyzis of the responsiveness of gastrointestinal tumor cell lines to drug therapy: A transportome approach
Pharmacological Research, Vol. 113, pp. 364-375
2012
-
No correlation between the expression of FXR and genes involved in multidrug resistance phenotype of primary liver tumors
Molecular Pharmaceutics, Vol. 9, Núm. 6, pp. 1693-1704
-
Up-regulation of FXR isoforms is not required for stimulation of the expression of genes involved in the lack of response of colon cancer to chemotherapy
Pharmacological Research, Vol. 66, Núm. 5, pp. 419-427
2007
-
Oral insulin-mimetic compounds that act independently of insulin
Diabetes, Vol. 56, Núm. 2, pp. 486-493